FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157218960> ?p ?o ?g. }

• W3157218960 abstract "RATIONALE: SARS-CoV-2 gains entrance to airway epithelial cells (AECs) through binding of the viral spike protein to the angiotensin-converting enzyme 2 (ACE2) on the cell surface. However, ACE-2 also converts angiotensin II into angiotensin-(1-7) and counterbalances the renin-angiotensin-aldosterone system, with resultant protective effects in the cardiovascular system. Some data suggest that two common antihypertension medications (angiotensin II receptor blockers, ARBs;and angiotensin-converting-enzyme inhibitors, AECi) may increase ACE-2 expression in heart and kidney cells, fueling debate about how these widely used medications may modulate SARS-CoV2 infectivity and risk of COVID-19. Aim: Determine whether exposure of bronchial AECs to the ARB losartan or the ACEi captopril modulate expression of ACE-2 by AECs and/or SARS CoV2 replication. Methods: Primary bronchial AECs from children and adults (n=18;ages 8-75 yrs.) were differentiated ex vivo at an air-liquid interface to generate organotypic cultures. Cultures were treated with captopril (1μM) or losartan (2μM) added to basolateral media with each culture media change starting 72 hrs. before infection with SARS-CoV-2. In a biosafety level 3 (BSL-3) facility, cultures were infected with SARS-CoV-2 isolate USA-WA1/2020 at a multiplicity of infection (MOI) of 0.5. At 96 hrs. following infection, RNA and protein were isolated from cultures. SARS-CoV-2 replication in cultures was assessed with quantitative PCR, and quantified as viral copy number/ng RNA. ACE-2 expression was assessed by qPCR. Results: Neither captopril nor losartan treatment significantly changed AEC-2 expression by AECs as compared to untreated AEC cultures or SARS-CoV-2 infected AEC cultures without captopril or losartan treatment. At 96 hrs. following infection, SARS-CoV-2 copy number/ng RNA was not significantly different between untreated AEC cultures (median 1752, 95% CI 213 - 8599), cultures treated with captopril (median 448.6, 95% CI 160 - 3051), or cultures treated with lorsartan (median 640, 95% CI 127 - 1610;Kruskal-Wallis ANOVA p=0.4). Conclusion: These findings suggest that at the level of the airway epithelium neither the ACEi captopril or ARB losartan significantly modify expression of the SARS-CoV-2 entry factor ACE-2, nor does either medication effect the replication of SARS-CoV-2. This ex vivo data is reassuring and is consistent with evolving clinical data suggesting ACEi and ARB medications do not increase the risk for poor prognosis with COVID-19, and may actually reduce the risk of COVID-19 disease." @default.
• W3157218960 created "2021-05-10" @default.
• W3157218960 creator A5022390505 @default.
• W3157218960 creator A5024851562 @default.
• W3157218960 creator A5031922617 @default.
• W3157218960 creator A5052547029 @default.
• W3157218960 creator A5066038030 @default.
• W3157218960 creator A5070427565 @default.
• W3157218960 creator A5086923719 @default.
• W3157218960 date "2021-05-01" @default.
• W3157218960 modified "2023-09-27" @default.
• W3157218960 title "Effect of Angiotensin Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Treatment of Differentiated Primary Airway Epithelial Cells on Ace2 Expression and SarsCoV2 Replication" @default.
• W3157218960 doi "https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1284" @default.
• W3157218960 hasPublicationYear "2021" @default.
• W3157218960 type Work @default.
• W3157218960 sameAs 3157218960 @default.
• W3157218960 citedByCount "0" @default.
• W3157218960 crossrefType "proceedings-article" @default.
• W3157218960 hasAuthorship W3157218960A5022390505 @default.
• W3157218960 hasAuthorship W3157218960A5024851562 @default.
• W3157218960 hasAuthorship W3157218960A5031922617 @default.
• W3157218960 hasAuthorship W3157218960A5052547029 @default.
• W3157218960 hasAuthorship W3157218960A5066038030 @default.
• W3157218960 hasAuthorship W3157218960A5070427565 @default.
• W3157218960 hasAuthorship W3157218960A5086923719 @default.
• W3157218960 hasConcept C104849204 @default.
• W3157218960 hasConcept C123915805 @default.
• W3157218960 hasConcept C12590798 @default.
• W3157218960 hasConcept C126322002 @default.
• W3157218960 hasConcept C159047783 @default.
• W3157218960 hasConcept C170493617 @default.
• W3157218960 hasConcept C181199279 @default.
• W3157218960 hasConcept C198710026 @default.
• W3157218960 hasConcept C27016395 @default.
• W3157218960 hasConcept C2775946041 @default.
• W3157218960 hasConcept C2779134260 @default.
• W3157218960 hasConcept C2779611605 @default.
• W3157218960 hasConcept C2908929049 @default.
• W3157218960 hasConcept C2910482119 @default.
• W3157218960 hasConcept C3008058167 @default.
• W3157218960 hasConcept C502942594 @default.
• W3157218960 hasConcept C524204448 @default.
• W3157218960 hasConcept C55493867 @default.
• W3157218960 hasConcept C71924100 @default.
• W3157218960 hasConcept C84393581 @default.
• W3157218960 hasConcept C86803240 @default.
• W3157218960 hasConcept C98274493 @default.
• W3157218960 hasConceptScore W3157218960C104849204 @default.
• W3157218960 hasConceptScore W3157218960C123915805 @default.
• W3157218960 hasConceptScore W3157218960C12590798 @default.
• W3157218960 hasConceptScore W3157218960C126322002 @default.
• W3157218960 hasConceptScore W3157218960C159047783 @default.
• W3157218960 hasConceptScore W3157218960C170493617 @default.
• W3157218960 hasConceptScore W3157218960C181199279 @default.
• W3157218960 hasConceptScore W3157218960C198710026 @default.
• W3157218960 hasConceptScore W3157218960C27016395 @default.
• W3157218960 hasConceptScore W3157218960C2775946041 @default.
• W3157218960 hasConceptScore W3157218960C2779134260 @default.
• W3157218960 hasConceptScore W3157218960C2779611605 @default.
• W3157218960 hasConceptScore W3157218960C2908929049 @default.
• W3157218960 hasConceptScore W3157218960C2910482119 @default.
• W3157218960 hasConceptScore W3157218960C3008058167 @default.
• W3157218960 hasConceptScore W3157218960C502942594 @default.
• W3157218960 hasConceptScore W3157218960C524204448 @default.
• W3157218960 hasConceptScore W3157218960C55493867 @default.
• W3157218960 hasConceptScore W3157218960C71924100 @default.
• W3157218960 hasConceptScore W3157218960C84393581 @default.
• W3157218960 hasConceptScore W3157218960C86803240 @default.
• W3157218960 hasConceptScore W3157218960C98274493 @default.
• W3157218960 hasLocation W31572189601 @default.
• W3157218960 hasOpenAccess W3157218960 @default.
• W3157218960 hasPrimaryLocation W31572189601 @default.
• W3157218960 hasRelatedWork W1983513268 @default.
• W3157218960 hasRelatedWork W2000817079 @default.
• W3157218960 hasRelatedWork W2034551019 @default.
• W3157218960 hasRelatedWork W2050371471 @default.
• W3157218960 hasRelatedWork W2055306864 @default.
• W3157218960 hasRelatedWork W2101075976 @default.
• W3157218960 hasRelatedWork W2108312009 @default.
• W3157218960 hasRelatedWork W2331233360 @default.
• W3157218960 hasRelatedWork W3004935083 @default.
• W3157218960 hasRelatedWork W3158929090 @default.
• W3157218960 isParatext "false" @default.
• W3157218960 isRetracted "false" @default.
• W3157218960 magId "3157218960" @default.
• W3157218960 workType "article" @default.